Pharma execs raise concerns about Trump’s plans for the FDA; Merck ends study of experimental Alzheimer’s drug; Amgen seeks new indication for Blincyto
Five things for pharma marketers to know: Tuesday, February 7, 2017
Despite their blockbuster status and distinction as the world’s most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.
GSK and Propeller Health’s smart inhaler aims to improve adherence in clinical trials
FDA solicits public comment to study online character space limit; Biogen’s Spinraza shows positive results in SMA study; Valeant cuts earnings forecast
Interview | Jeanne Martel, ClinicalMind
October 11, 2016
5:14 pm
Jeanne Martel, president and partner at ClinicalMind, highlights her company’s vision and role in communication and technology with MM&M’s Jaimy Lee. This video was sponsored by ClinicalMind.
Five things for pharma marketers to know: Tuesday, December 8, 2015
Aggressive treatment of blood pressure reduces deaths; AstraZeneca’s experimental lupus drug cut disease activity in trial; Sophiris Bio reports results for enlarged prostate drug
Five things for pharma marketers to know: Tuesday, November 3, 2015
GSK partners with other drugmakers to bolster pipeline; Pfizer makes deal in South Africa for Prevnar 13; the FDA issues guidance on HIV biologic development